Fiercely Pursuing and Delivering Therapies

Dedicated to quality and driven by excellence, we are committed to improving the lives of patients worldwide.

Creating Hope and New Opportunities

Our pipeline of cell therapies includes agents across hematologic and solid tumors. We focus on diseases that are considered intractable and incurable.

Transforming the World of Oncology and Medicine

We are a 1,000+ team driven by our passion for developing cutting-edge cell therapies.

Our news

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 5, 2024

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Nov 4, 2024

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Oct 24, 2024

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Oct 3, 2024

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 27, 2024

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 20, 2024

Why we do what we do

We focus on serious and intractable diseases to help patients around the world.

PLAY VIDEO

Learn about us

Explore our technologies

We are technology agnostic in targeting hematologic malignancies and solid tumors. We are exploring 4 different technologies to help treat disease.

Meet our leadership team

Our leaders bring significant expertise from some of the world’s largest pharma companies.

Understand our capabilities

We are an end-to-end cell therapy company. Our capabilities extend from discovery to commercialization.

Work with us

We offer a variety of career choices that support the development of novel therapies.

Our pipeline

Our pipeline is comprised of investigational agents and innovative technologies in personalized medicine. We are devoted to exploring the potential of cell therapies to treat diseases that are considered intractable and incurable, including hematological malignancies and solid tumors.

LEARN MORE

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.